Fig. 4: Consort diagram for the CAP012B study.

The dosing groups evaluating different administration strategies for bNAbs. CAP256V2LS and VRC07-523LS were delivered subcutaneously, both with and without recombinant human hyaluronidase (ENHANZE™ Drug Product, or EDP).